|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/10<sup>4</sup>ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91).
|
30612065 |
2019 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
In BCR-ABL1-negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia.
|
31340059 |
2019 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current study reported cases of two patients with an initial diagnosis of ET in the presence of JAK2V617F mutation and BCR‑ABL translocation by fluorescent in situ hybridization.
|
29845291 |
2018 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF.
|
29560522 |
2018 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Essential thrombocythemia (ET) is a BCL-ABL1-negative myeloproliferative neoplasm.
|
28415571 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET).
|
29134817 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
|
28406068 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively.
|
28335073 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
|
26933174 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of BCR-ABL1 is critical in the distinction of ET from CML.
|
26754830 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hence, we examined a cohort of 123 myeloproliferative neoplasm (MPN) patients without BCR-ABL1 rearrangement and additional ET patients (n=96) for coexistence of JAK2 and CALR mutations.
|
27486987 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polycythaemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (MF), are the most common myeloproliferative neoplasms (MPN) in patients without the BCR-ABL1 gene rearrangement.
|
23986553 |
2014 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV).
|
22793267 |
2013 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which fall into distinct categories based on a number of characteristics including the presence of the BCR-ABL1 gene fusion (chronic myelogenous leukemia) or the JAK2(V617F) mutation (polycythemia vera, primary myelofibrosis, and essential thrombocythemia).
|
22847163 |
2012 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP).
|
22170483 |
2012 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
22035746 |
2011 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
20002154 |
2010 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative genomic hybridization (CGH), using oligo arrays with either 44,000 or 105,000 oligonucleotides, was performed on granulocyte-derived DNA from 71 patients with BCR-ABL-negative classic myeloproliferative neoplasms (MPNs): 32 primary myelofibrosis (PMF), 26 polycythemia vera (PV) and 13 essential thrombocythemia (ET).
|
18937974 |
2009 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), entered the spotlight in 2005 when the unique somatic acquired JAK2 V617F mutation was described in >95% of PV and in 50% of ET and PMF patients.
|
18769448 |
2008 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis and management of the BCR-ABL-negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase-activating JAK2V617F mutation in 2005.
|
18024651 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We set-up a multiplex real-time polymerase chain reaction assay followed by capillary electrophoresis, designed to simultaneously screen the two main genetic lesions associated with CMDs, i.e. the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F mutation that characterises polycythaemia vera and a proportion of cases of essential thrombocythemia and idiopathic myelofibrosis.
|
17285276 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metaplasia (44% of n = 127) bear the identical mutation, as do a few individuals with myelodysplastic syndromes or an atypical myeloid disorder (7% of n = 556).
|
16321848 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients presenting clinical features of PT expressing the Ph chromosome or the BCR/ABL fusion gene have been well documented but, to our knowledge, this is the first report of evolution from typical PT to chronic myeloid leukemia.
|
16682291 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We detected the messenger RNA expression of the bcr-abl gene using reverse transcription-polymerase chain reaction in peripheral-blood leukocytes (PBLs) from 63 patients with myeloproliferative disorders (including CML, ET, and polycythemia vera [PV]) and 51 normal, healthy volunteers.
|
14966468 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
|
14966468 |
2004 |